Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Agenus Stock Jumped Higher Today

By Maxx Chatsko – Updated Jun 22, 2020 at 4:23PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The development-stage biopharma delivered two encouraging updates.

What happened

Shares of Agenus (AGEN -0.48%) rose as much as 10.8% today after the company reported a licensing deal in China and highlighted results from an early-stage study. The development-stage biopharma licensed two drug candidates to Betta Pharmaceuticals for a total up-front payment of $35 million. It also showed early evidence that drug combinations including AGEN1181 have promising potential in certain difficult-to-treat solid tumors.

The licensing agreement will boost the company's cash position, which stood at $92 million at the end of March. Meanwhile, the early results from AGEN1181 provide further evidence the company's unique drug-design strategy holds promise.

At the close of trading Monday, the small-cap stock had settled to a 10.4% gain.

A series of ascending arrows on a chalkboard.

Image source: Getty Images.

So what

Under the licensing agreement, Agenus has granted Betta Pharmaceuticals rights to balstilimab (AGEN2034) and zalifrelimab (AGEN1884) in China. The drug candidates target PD-1 and CTLA-4, respectively, two proteins that play a crucial role in solid-tumor cancers. Agenus will receive an up-front cash payment of $15 million and an equity investment of $20 million. It can receive up to $100 million in additional milestone payments plus royalties.

As for AGEN1181, Agenus advertised a presentation at American Association for Cancer Research annual meeting. The early-stage results suggest combining the engineered antibody with cell therapies could drive complete responses in cancers that are resistant to PD-1 therapies alone. It provides further evidence suggesting the company's approach to drug design -- engineering the crystallizable fragment (Fc) of antibodies -- can generate enhanced immune responses against solid-tumor cancers.

Now what

Agenus is now valued at just over $700 million. On the one hand, that's close to an all-time high. On the other hand, it shows Wall Street isn't necessarily blown away by recent developments. Investors can't be too surprised given the early nature of results for AGEN1181. For now, this biopharma stock remains a relatively high-risk investment.

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Agenus Inc. Stock Quote
Agenus Inc.
$2.05 (-0.48%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.